サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1750816

遺伝子治療プラットフォームの市場規模、シェア、動向分析レポート：プラットフォームタイプ別、治療用途別、送達モード別、最終用途別、地域別、セグメント予測、2025年～2030年

Gene Therapy Platform Market Size, Share & Trends Analysis Report By Platform Type (Viral Vector Platforms, Non-Viral Vector Platforms), By Therapeutic Application, By Delivery Mode, By End Use, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.35円
遺伝子治療プラットフォームの市場規模、シェア、動向分析レポート：プラットフォームタイプ別、治療用途別、送達モード別、最終用途別、地域別、セグメント予測、2025年～2030年
出版日: 2025年05月23日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

遺伝子治療プラットフォームの市場規模と動向

遺伝子治療プラットフォームの世界市場規模は2024年に21億4,000万米ドルと推定され、2025～2030年にかけてCAGR 15.2％で成長すると予測されています。

この成長は、急速な技術進歩、遺伝性疾患や慢性疾患の有病率の増加、バイオ医薬品研究への投資と資金調達の拡大、迅速な承認を促進する支持的な規制枠組みなど、いくつかの主要な促進要因によってもたらされます。

ウイルスベクタ技術、CRISPRを含む遺伝子編集ツール、AIの統合、製造における自動化などの技術革新は、治療の精度と生産効率を高めています。例えば、キャタレントは2023年3月、遺伝子治療の開発を加速するため、UpTempo AAVプラットフォームを強化します。

希少疾患や遺伝性疾患を対象とした遺伝子治療のFDA承認件数の増加は、これらのプラットフォームの臨床的可能性を検証し、投資と研究開発を促しています。例えば、2023年12月[、Exagamglogene autotemcel（Casgevy）のようなCRISPRベースの治療法は、鎌状赤血球症とβ-サラセミアに対してFDAの承認を受け、遺伝子治療における重要なマイルストーンとなりました。これらの画期的な進歩は、このセグメントを前進させ、様々な遺伝性疾患に対するより効率的な技術を可能にしています。

遺伝性疾患や慢性疾患の有病率が世界的に上昇していることが、分子レベルで疾患を標的とする遺伝子治療への需要を煽っています。嚢胞性線維症、血友病、脊髄性筋萎縮症、各種がんなどの疾患は、治癒の可能性がある遺伝子治療アプローチで治療されるようになってきています。世界保健機関（WHO）は2024年、世界的にがん患者が急増すると予測しており、2050年までに新たに発生するがん患者は3,500万人を超えると予想されています。このような患者数の増加は、先進的治療に対する緊急の需要を生み出し、アンメット・メディカル・ニーズに対応するための遺伝子治療技術への投資と技術革新を促進します。

さらに、革新的な治療法に対する規制当局の支援が市場成長を後押ししています。FDAや欧州医薬品庁（EMA）などの規制機関は、遺伝子治療の変革の可能性を認識し、その承認プロセスを合理化しています。さらに、ファスト・トラック指定や希少疾病用医薬品（オーファンドラッグ）ステータスなどの規制上の優遇措置が、遺伝子治療の開発をさらに後押ししています。これらの措置は、開発期間を短縮し、アンメット・メディカル・ニーズに対応する新しい治療法の導入を促進するのに役立っています。

COVID-19の大流行は市場に大きな影響を与え、臨床検査、製造、サプライチェーンを混乱させました。COVID-19ワクチン製造のための原料の需要増は不足を引き起こし、遺伝子治療製造に不可欠な成分の入手に影響を与えました。このような課題にもかかわらず、パンデミックは技術革新にも拍車をかけ、一部の遺伝子治療開発企業はCOVID-19関連の治療やワクチンに取り組み、遺伝子治療セグメントの回復力と可能性を浮き彫りにしました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 遺伝子治療プラットフォーム市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場の展望
    • 関連/補助市場展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
    • 産業の課題と機会の分析
  • 遺伝子治療プラットフォーム市場分析ツール
    • ポーター分析
    • PESTEL分析
  • 規制の枠組み
  • 新興技術
  • COVID-19による遺伝子治療プラットフォーム市場への影響
  • 使用事例と洞察

第4章 遺伝子治療プラットフォーム市場：プラットフォームタイプ別、推定・動向分析

  • 定義と範囲
  • プラットフォームタイプ市場シェア分析、2024年と2030年
  • セグメントダッシュボード
  • 遺伝子治療プラットフォーム市場：プラットフォームタイプ別、2018～2030年
  • ウイルスベクタプラットフォーム
    • アデノ随伴ウイルス（AAV）
    • レンチウイルス
    • レトロウイルス
    • アデノウイルス
    • 単純ヘルペスウイルス（HSV）
  • 非ウイルスベクタプラットフォーム
    • 脂質ナノ粒子（LNP）
    • エレクトロポレーションとマイクロインジェクションプラットフォーム
    • ポリマーベースのデリバリーシステム
    • 裸のDNA/RNA送達
  • 遺伝子編集プラットフォーム
    • CRISPR-Casシステム
    • TALENs
    • ZFN

第5章 遺伝子治療プラットフォーム市場：治療用途別、推定・動向分析

  • 定義と範囲
  • 治療用途市場シェア分析、2024年と2030年
  • セグメントダッシュボード
  • 遺伝子治療プラットフォーム市場：治療用途別、2018～2030年
  • 腫瘍学
  • 希少遺伝性疾患
  • 心血管疾患
  • 神経疾患
  • 眼科疾患
  • 血液疾患（例：血友病、鎌状赤血球症）
  • 筋骨格系障害
  • 感染症（例：HIV、 COVID-19の補助療法）

第6章 遺伝子治療プラットフォーム市場：送達モード別、推定・動向分析

  • 定義と範囲
  • 送達モード市場シェア分析、2024年と2030年
  • セグメントダッシュボード
  • 遺伝子治療プラットフォーム市場：送達モード別、2018～2030年
  • 生体内遺伝子治療
  • 体外遺伝子治療
    • 自家細胞を用いた遺伝子治療
    • 同種細胞を用いた遺伝子治療
  • その他（原位置遺伝子治療）

第7章 遺伝子治療プラットフォーム市場：最終用途別、推定・動向分析

  • 定義と範囲
  • 最終用途市場シェア分析、2024年と2030年
  • セグメントダッシュボード
  • 遺伝子治療プラットフォーム市場：最終用途別、2018～2030年
  • 製薬・バイオテクノロジー企業
  • 学術研究機関
  • 契約開発製造組織（CDMO）
  • 病院と遺伝子治療センター

第8章 遺伝子治療プラットフォーム市場：プラットフォームタイプ、治療用途、送達方法、最終用途による地域別、推定・動向分析

  • 定義と範囲
  • 地域別市場シェア分析、2024年と2030年
  • 地域別市場ダッシュボード
  • 地域市場のスナップショット
  • SWOT分析
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 遺伝子治療プラットフォーム市場シェア（地域別、2024年と2030年、100万米ドル）
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • デンマーク
    • ノルウェー
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第9章 競合情勢

  • 企業分類
  • 企業の市場シェア分析
  • 企業ヒートマップ分析
  • 企業プロファイル
    • Lonza
    • BioIT
    • Autolomous Ltd
    • Hypertrust Patient Data Care（Accenture傘下）
    • IBM
    • L7 Informatics, Inc.
    • TrakCel
    • IDBS
    • Novartis
    • SAP SE
    • DEEP GENOMICS
    • ElevateBio
    • Sarepta Therapeutics, Inc.
    • CRISPR Therapeutics
    • Precision BioSciences
    • AstraZeneca
    • Andelyn Biosciences
    • Renova Therapeutics
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 North America gene therapy platform market estimates and forecasts, by platform type, 2018 - 2030 (USD Million)
  • Table 4 North America gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 5 North America gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 6 North America gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 7 U.S. gene therapy platform market estimates and forecasts, by platform type, 2018 - 2030 (USD Million)
  • Table 8 U.S. gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 9 U.S. gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 10 U.S. gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 11 Canada gene therapy platform market estimates and forecasts, by platform type, 2018 - 2030 (USD Million)
  • Table 12 Canada gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 13 Canada gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 14 Canada gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 15 Mexico gene therapy platform market estimates and forecasts, by platform type, 2018 - 2030 (USD Million)
  • Table 16 Mexico gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 17 Mexico gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 18 Mexico gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe gene therapy platform market estimates and forecasts, by platform type, 2018 - 2030 (USD Million)
  • Table 20 Europe gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 21 Europe gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 22 Europe gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 23 UK gene therapy platform market estimates and forecasts, by platform type, 2018 - 2030 (USD Million)
  • Table 24 UK gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 25 UK gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 26 UK gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 27 Germany gene therapy platform market estimates and forecasts, by platform type, 2018 - 2030 (USD Million)
  • Table 28 Germany gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 29 Germany gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 30 Germany gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 31 France gene therapy platform market estimates and forecasts, by platform type, 2018 - 2030 (USD Million)
  • Table 32 France gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 33 France gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 34 France gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 35 Italy gene therapy platform market estimates and forecasts, by platform type, 2018 - 2030 (USD Million)
  • Table 36 Italy gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 37 Italy gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 38 Italy gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 39 Spain gene therapy platform market estimates and forecasts, by platform type, 2018 - 2030 (USD Million)
  • Table 40 Spain gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 41 Spain gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 42 Spain gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 43 Sweden gene therapy platform market estimates and forecasts, by platform type, 2018 - 2030 (USD Million)
  • Table 44 Sweden gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 45 Sweden gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 46 Sweden gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 47 Denmark gene therapy platform market estimates and forecasts by platform type, 2018 - 2030 (USD Million)
  • Table 48 Denmark gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 49 Denmark gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 50 Denmark gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 51 Norway gene therapy platform market estimates and forecasts by platform type, 2018 - 2030 (USD Million)
  • Table 52 Norway gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 53 Norway gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 54 Norway gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 55 Asia Pacific gene therapy platform market estimates and forecasts by platform type, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 59 Japan gene therapy platform market estimates and forecasts by platform type, 2018 - 2030 (USD Million)
  • Table 60 Japan gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 61 Japan gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 62 Japan gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 63 China gene therapy platform market estimates and forecasts by platform type, 2018 - 2030 (USD Million)
  • Table 64 China gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 65 China gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 66 China gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 67 India gene therapy platform market estimates and forecasts by platform type, 2018 - 2030 (USD Million)
  • Table 68 India gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 69 India gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 70 India gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 71 Australia gene therapy platform market estimates and forecasts, by platform type, 2018 - 2030 (USD Million)
  • Table 72 Australia gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 73 Australia gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 74 Australia gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 75 South Korea gene therapy platform market estimates and forecasts by platform type, 2018 - 2030 (USD Million)
  • Table 76 South Korea gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 77 South Korea gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 78 South Korea gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 79 Thailand gene therapy platform market estimates and forecasts, by platform type, 2018 - 2030 (USD Million)
  • Table 80 Thailand gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 81 Thailand gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 82 Thailand gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 83 Latin America gene therapy platform market estimates and forecasts by platform type, 2018 - 2030 (USD Million)
  • Table 84 Latin America gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 85 Latin America gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 86 Latin America gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 87 Brazil gene therapy platform market estimates and forecasts, by platform type, 2018 - 2030 (USD Million)
  • Table 88 Brazil gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 89 Brazil gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 90 Brazil gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 91 Argentina gene therapy platform market estimates and forecasts, by platform type, 2018 - 2030 (USD Million)
  • Table 92 Argentina gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 93 Argentina gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 94 Argentina gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 95 MEA gene therapy platform market estimates and forecasts, by platform type, 2018 - 2030 (USD Million)
  • Table 96 MEA gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 97 MEA gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 98 MEA gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 99 South Africa gene therapy platform market estimates and forecasts, by platform type, 2018 - 2030 (USD Million)
  • Table 100 South Africa gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 101 South Africa gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 102 South Africa gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 103 Saudi Arabia gene therapy platform market estimates and forecasts, by platform type, 2018 - 2030 (USD Million)
  • Table 104 Saudi Arabia gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 105 Saudi Arabia gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 106 Saudi Arabia gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 107 UAE gene therapy platform market estimates and forecasts, by platform type, 2018 - 2030 (USD Million)
  • Table 108 UAE gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 109 UAE gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 110 UAE gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 111 Kuwait gene therapy platform market estimates and forecasts, by platform type, 2018 - 2030 (USD Million)
  • Table 112 Kuwait gene therapy platform market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 113 Kuwait gene therapy platform market estimates and forecasts by delivery method, 2018 - 2030 (USD Million)
  • Table 114 Kuwait gene therapy platform market estimates and forecasts by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Gene Therapy Platform Market Segmentation
  • Fig. 2 Information Procurement
  • Fig. 3 Data Analysis Models
  • Fig. 4 Market Formulation and Validation
  • Fig. 5 Data Validating & Publishing
  • Fig. 6 Market Snapshot
  • Fig. 7 Segment Snapshot
  • Fig. 8 Competitive Landscape Snapshot
  • Fig. 9 Gene Therapy Platform- Market Size and Growth Prospects (USD Million)
  • Fig. 10 Gene Therapy Platform Market: Industry Value Chain Analysis
  • Fig. 11 Gene Therapy Platform Market: Market Dynamics
  • Fig. 12 Gene Therapy Platform Market: PORTER's Analysis
  • Fig. 13 Gene Therapy Platform Market: PESTEL Analysis
  • Fig. 14 Gene Therapy Platform Market, by Platform Type: Key Takeaways
  • Fig. 15 Gene Therapy Platform Market, by Platform Type: Market Share, 2024 & 2030
  • Fig. 16 Viral Vector Platforms Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 17 Adeno-associated Virus (AAV) Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 18 Lentivirus Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 19 Retrovirus Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 20 Adenovirus Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 21 Herpes Simplex Virus (HSV) Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 22 Non-Viral Vector Platforms Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 23 Lipid Nanoparticles (LNPs) Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 24 Electroporation & Microinjection Platforms Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 25 Polymer-based Delivery Systems Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 26 Naked DNA/RNA Delivery Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 27 Gene Editing Platforms Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 28 CRISPR-Cas Systems Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 29 TALENs Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 30 ZFNs Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 31 Gene Therapy Platform Market, by Application: Key Takeaways
  • Fig. 32 Gene Therapy Platform Market, by Application: Market Share, 2024 & 2030
  • Fig. 33 Oncology Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 34 Rare Genetic Disorders Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 35 Cardiovascular Diseases Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 36 Neurological Disorders Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 37 Ophthalmic Diseases Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 38 Hematological Disorders (e.g., Hemophilia, Sickle Cell) Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 39 Musculoskeletal Disorders Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 40 Infectious Diseases (e.g., HIV, COVID-19 adjunct therapies) Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 41 Gene Therapy Platform Market, by Delivery Method: Key Takeaways
  • Fig. 42 Gene Therapy Platform Market, by Delivery Method: Market Share, 2024 & 2030
  • Fig. 43 In Vivo Gene Therapy Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 44 Ex Vivo Gene Therapy Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 45 Autologous Cell-Based Gene Therapy Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 46 Allogeneic Cell-Based Gene Therapy Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 47 Others (In-situ Gene therapy) Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 48 Gene Therapy Platform Market, by End Use: Key Takeaways
  • Fig. 49 Gene Therapy Platform Market, by End Use: Market Share, 2024 & 2030
  • Fig. 50 Pharmaceutical & Biotechnology Companies Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 51 Academic & Research Institutions Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 52 Contract Development & Manufacturing Organizations (CDMOs) Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 53 Hospitals & Gene Therapy Centers Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 54 Gene Therapy Platform Market Revenue, by Region, 2024 & 2030 (USD Million)
  • Fig. 55 Regional Marketplace: Key Takeaways
  • Fig. 56 Regional Marketplace: Key Takeaways
  • Fig. 57 North America Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 U.S. Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Canada Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Mexico Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Europe Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 UK Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Germany Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 France Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Italy Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Spain Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Sweden Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Denmark Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Norway Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Asia Pacific Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Japan Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 China Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 India Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Australia Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Thailand Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Latin America Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Brazil Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Argentina Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 MEA Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Saudi Arabia Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 UAE Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 South Africa Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Kuwait Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key Company Categorization
  • Fig. 85 Company Market Positioning
  • Fig. 86 Key Company Market Share Analysis, 2024
  • Fig. 87 Strategic Framework
目次
Product Code: GVR-4-68040-589-6

Gene Therapy Platform Market Size & Trends:

The global gene therapy platform market size was estimated at USD 2.14 billion in 2024 and is projected to grow at a CAGR of 15.2% from 2025 to 2030. The growth is driven by several key drivers, including rapid technological advancements, increasing prevalence of genetic and chronic diseases, growing investments and funding in biopharmaceutical research, and supportive regulatory frameworks facilitating faster approvals.

Innovations in viral vector technologies, gene editing tools including CRISPR, integration of AI and automation in manufacturing are enhancing therapy precision and production efficiency. For instance, in March 2023, Catalent is enhancing its UpTempo AAV platform to speed up the development of gene therapies.

The increasing number of FDA approvals for gene therapies targeting rare and genetic diseases has validated the clinical potential of these platforms, encouraging investment and R&D. For instance, in December 2023[, CRISPR-based therapies, like Exagamglogene autotemcel (Casgevy), received FDA approval for sickle cell disease and beta-thalassemia, marking a significant milestone in gene therapy. These breakthroughs are pushing the field forward, enabling more efficient technology for various genetic disorders.

The rising prevalence of genetic disorders and chronic diseases worldwide, is fueling demand for gene therapies that target disease at the molecular level. Conditions such as cystic fibrosis, hemophilia, spinal muscular atrophy, and various cancers are increasingly treated with gene therapy approaches that offer potentially curative outcomes. The World Health Organization (WHO) in 2024 projected a sharp increase in cancer cases globally, with over 35 million new cases expected by 2050, up 77% from 2022. This growing patient pool creates urgent demand for advanced treatments, driving investment and innovation in gene therapy technologies to address unmet medical needs.

Moreover, regulatory support for innovative therapies is driving market growth. Regulatory agencies, including the FDA and the European Medicines Agency (EMA), have streamlined approval processes for gene therapies, recognizing their transformative potential. In addition, regulatory incentives such as fast-track designations and orphan drug status further support the development of gene therapies. These measures help reduce development timelines and encourage the introduction of new treatments to address unmet medical needs.

The COVID-19 pandemic significantly impacted the market, disrupting clinical trials, manufacturing, and supply chains. The increased demand for raw materials for COVID-19 vaccine production caused shortages, affecting the availability of essential components for gene therapy manufacturing. Despite these challenges, the pandemic also spurred innovation, with some gene therapy developers adapting their efforts toward COVID-19-related therapeutics and vaccines, highlighting the resilience and potential of the gene therapy sector.

Global Gene Therapy Platform Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global gene therapy platform market report based on platform type, application, delivery method, end use, and region.

  • Platform Type Outlook (Revenue, USD Million, 2018 - 2030)
  • Viral Vector Platforms
    • Adeno-associated Virus (AAV)
    • Lentivirus
    • Retrovirus
    • Adenovirus
    • Herpes Simplex Virus (HSV)
  • Non-Viral Vector Platforms
    • Lipid Nanoparticles (LNPs)
    • Electroporation & Microinjection Platforms
    • Polymer-based Delivery Systems
    • Naked DNA/RNA Delivery
  • Gene Editing Platforms
    • CRISPR-Cas Systems
    • TALENs
    • ZFNs
  • Application Outlook (Revenue, USD Million, 2018 - 2030)
  • Oncology
  • Rare Genetic Disorders
  • Cardiovascular Diseases
  • Neurological Disorders
  • Ophthalmic Diseases
  • Hematological Disorders (e.g., Hemophilia, Sickle Cell)
  • Musculoskeletal Disorders
  • Infectious Diseases (e.g., HIV, COVID-19 adjunct therapies)
  • Delivery Mode Outlook (Revenue, USD Million, 2018 - 2030)
  • In Vivo Gene Therapy
  • Ex Vivo Gene Therapy
    • Autologous Cell-Based Gene Therapy
    • Allogeneic Cell-Based Gene Therapy
  • Others (In-situ Gene therapy)
  • End Use Outlook (Revenue, USD Million, 2018 - 2030)
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutions
  • Contract Development & Manufacturing Organizations (CDMOs)
  • Hospitals & Gene Therapy Centers
  • Regional Outlook (Revenue, USD Million, 2018-2030)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Scope
    • 1.2.1. Platform Type
    • 1.2.2. Application
    • 1.2.3. Delivery Method
    • 1.2.4. End Use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
  • 1.5. Details of primary research
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
      • 1.7.1.1. Approach 1: Commodity flow approach
    • 1.7.2. Volume price analysis (Model 2)
      • 1.7.2.1. Approach 2: Volume price analysis
  • 1.8. Research Scope and Assumptions
    • 1.8.1. List of Secondary Sources
    • 1.8.2. List of Primary Sources
    • 1.8.3. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Platform Type Outlook
    • 2.2.2. Application Outlook
    • 2.2.3. Delivery Method Outlook
    • 2.2.4. End Use Outlook
    • 2.2.5. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Gene Therapy Platform Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers Analysis
      • 3.2.1.1. Rising prevalence of genetic disorders
      • 3.2.1.2. Advancements in gene editing technologies
      • 3.2.1.3. Supportive regulatory frameworks
      • 3.2.1.4. Growing investment and strategic partnerships
    • 3.2.2. Market Restraints Analysis
      • 3.2.2.1. High cost of development and treatment
    • 3.2.3. Industry Challenges and Opportunity Analysis
  • 3.3. Gene Therapy Platform Market Analysis Tools
    • 3.3.1. Porter's Analysis
      • 3.3.1.1. Bargaining power of the suppliers
      • 3.3.1.2. Bargaining power of the buyers
      • 3.3.1.3. Threats of substitution
      • 3.3.1.4. Threats from new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social Landscape
      • 3.3.2.3. Technological Landscape
      • 3.3.2.4. Environmental Landscape
      • 3.3.2.5. Legal Landscape
  • 3.4. Regulatory Framework
  • 3.5. Emerging Technologies
  • 3.6. Impact of COVID 19 on the Gene Therapy Platform Market
  • 3.7. Case Study & Insights

Chapter 4. Gene Therapy Platform Market: Platform Type Estimates & Trend Analysis

  • 4.1. Definition and Scope
  • 4.2. Platform Type Market Share Analysis, 2024 & 2030
  • 4.3. Segment Dashboard
  • 4.4. Gene Therapy Platform Market: By Platform Type, 2018 to 2030
  • 4.5. Viral Vector Platforms
    • 4.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. Adeno-associated Virus (AAV)
      • 4.5.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Lentivirus
      • 4.5.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.4. Retrovirus
      • 4.5.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.5. Adenovirus
      • 4.5.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.6. Herpes Simplex Virus (HSV)
      • 4.5.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Non-Viral Vector Platforms
    • 4.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.2. Lipid Nanoparticles (LNPs)
      • 4.6.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.3. Electroporation & Microinjection Platforms
      • 4.6.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.4. Polymer-based Delivery Systems
      • 4.6.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.5. Naked DNA/RNA Delivery
      • 4.6.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Gene Editing Platforms
    • 4.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.2. CRISPR-Cas Systems
      • 4.7.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.3. TALENs
      • 4.7.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.4. ZFNs
      • 4.7.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Gene Therapy Platform Market: Application Estimates & Trend Analysis

  • 5.1. Definition and Scope
  • 5.2. Application Market Share Analysis, 2024 & 2030
  • 5.3. Segment Dashboard
  • 5.4. Gene Therapy Platform Market: By Application, 2018 to 2030
  • 5.5. Oncology
    • 5.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Rare Genetic Disorders
    • 5.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Cardiovascular Diseases
    • 5.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Neurological Disorders
    • 5.8.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Ophthalmic Diseases
    • 5.9.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.10. Hematological Disorders (e.g., Hemophilia, Sickle Cell)
    • 5.10.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.11. Musculoskeletal Disorders
    • 5.11.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.12. Infectious Diseases (e.g., HIV, COVID-19 adjunct therapies)
    • 5.12.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Gene Therapy Platform Market: Delivery Method Estimates & Trend Analysis

  • 6.1. Definition and Scope
  • 6.2. Delivery Mode Market Share Analysis, 2024 & 2030
  • 6.3. Segment Dashboard
  • 6.4. Gene Therapy Platform Market: By Delivery Mode, 2018 to 2030
  • 6.5. In Vivo Gene Therapy
    • 6.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Ex Vivo Gene Therapy
    • 6.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Autologous Cell-Based Gene Therapy
      • 6.6.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Allogeneic Cell-Based Gene Therapy
      • 6.6.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Others (In-situ Gene therapy)
    • 6.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Gene Therapy Platform Market: End Use Estimates & Trend Analysis

  • 7.1. Definition and Scope
  • 7.2. End Use Market Share Analysis, 2024 & 2030
  • 7.3. Segment Dashboard
  • 7.4. Gene Therapy Platform Market: By End Use, 2018 to 2030
  • 7.5. Pharmaceutical & Biotechnology Companies
    • 7.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Academic & Research Institutions
    • 7.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Contract Development & Manufacturing Organizations (CDMOs)
    • 7.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Hospitals & Gene Therapy Centers
    • 7.8.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Gene Therapy Platform Market: Regional Estimates & Trend Analysis by Platform Type, Therapeutic Application, Delivery Method, and End Use

  • 8.1. Definition and Scope
  • 8.2. Regional Market Share Analysis, 2024 & 2030
  • 8.3. Regional Market Dashboard
  • 8.4. Regional Market Snapshot
  • 8.5. SWOT Analysis
    • 8.5.1. North America
    • 8.5.2. Europe
    • 8.5.3. Asia Pacific
    • 8.5.4. Latin America
    • 8.5.5. Middle East & Africa
  • 8.6. Gene Therapy Platform Market Share, By Region, 2024 & 2030, USD Million
  • 8.7. North America
    • 8.7.1. North America Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.2. U.S.
      • 8.7.2.1. U.S. Key Country Dynamics
      • 8.7.2.2. Regulatory Landscape
      • 8.7.2.3. Competitive Insights
      • 8.7.2.4. U.S. Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Canada
      • 8.7.3.1. Canada Key Country Dynamics
      • 8.7.3.2. Regulatory Landscape
      • 8.7.3.3. Competitive Insights
      • 8.7.3.4. Canada Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.4. Mexico
      • 8.7.4.1. Mexico Key Country Dynamics
      • 8.7.4.2. Regulatory Landscape
      • 8.7.4.3. Competitive Insights
      • 8.7.4.4. Mexico Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8. Europe
    • 8.8.1. Europe Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.2. UK
      • 8.8.2.1. UK Key Country Dynamics
      • 8.8.2.2. Regulatory Landscape
      • 8.8.2.3. Competitive Insights
      • 8.8.2.4. U.K. Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Germany
      • 8.8.3.1. Germany Key Country Dynamics
      • 8.8.3.2. Regulatory Landscape
      • 8.8.3.3. Competitive Insights
      • 8.8.3.4. Germany Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. France
      • 8.8.4.1. France Key Country Dynamics
      • 8.8.4.2. Regulatory Landscape
      • 8.8.4.3. Competitive Insights
      • 8.8.4.4. France Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Italy
      • 8.8.5.1. Italy Key Country Dynamics
      • 8.8.5.2. Regulatory Landscape
      • 8.8.5.3. Competitive Insights
      • 8.8.5.4. Italy Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.6. Spain
      • 8.8.6.1. Spain Key Country Dynamics
      • 8.8.6.2. Regulatory Landscape
      • 8.8.6.3. Competitive Insights
      • 8.8.6.4. Spain Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.7. Sweden
      • 8.8.7.1. Sweden Key Country Dynamics
      • 8.8.7.2. Regulatory Landscape
      • 8.8.7.3. Competitive Insights
      • 8.8.7.4. Sweden Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.8. Denmark
      • 8.8.8.1. Denmark Key Country Dynamics
      • 8.8.8.2. Regulatory Landscape
      • 8.8.8.3. Competitive Insights
      • 8.8.8.4. Denmark Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.9. Norway
      • 8.8.9.1. Norway Key Country Dynamics
      • 8.8.9.2. Regulatory Landscape
      • 8.8.9.3. Competitive Insights
      • 8.8.9.4. Norway Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.9. Asia Pacific
    • 8.9.1. Asia Pacific Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.9.2. China
      • 8.9.2.1. China Key Country Dynamics
      • 8.9.2.2. Regulatory Landscape
      • 8.9.2.3. Competitive Insights
      • 8.9.2.4. China Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.9.3. Japan
      • 8.9.3.1. Japan Key Country Dynamics
      • 8.9.3.2. Regulatory Landscape
      • 8.9.3.3. Competitive Insights
      • 8.9.3.4. Japan Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.9.4. India
      • 8.9.4.1. India Key Country Dynamics
      • 8.9.4.2. Regulatory Landscape
      • 8.9.4.3. Competitive Insights
      • 8.9.4.4. India Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.9.5. South Korea
      • 8.9.5.1. South Korea Key Country Dynamics
      • 8.9.5.2. Regulatory Landscape
      • 8.9.5.3. Competitive Insights
      • 8.9.5.4. South Korea Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.9.6. Australia
      • 8.9.6.1. Australia Key Country Dynamics
      • 8.9.6.2. Regulatory Landscape
      • 8.9.6.3. Competitive Insights
      • 8.9.6.4. Australia Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.9.7. Thailand
      • 8.9.7.1. Thailand Key Country Dynamics
      • 8.9.7.2. Regulatory Landscape
      • 8.9.7.3. Competitive Insights
      • 8.9.7.4. Thailand Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.10. Latin America
    • 8.10.1. Latin America Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.10.2. Brazil
      • 8.10.2.1. Brazil Key Country Dynamics
      • 8.10.2.2. Regulatory Landscape
      • 8.10.2.3. Competitive Insights
      • 8.10.2.4. Brazil Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.10.3. Argentina
      • 8.10.3.1. Argentina Key Country Dynamics
      • 8.10.3.2. Regulatory Landscape
      • 8.10.3.3. Competitive Insights
      • 8.10.3.4. Argentina Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.11. Middle East and Africa
    • 8.11.1. Middle East and Africa Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.11.2. South Africa
      • 8.11.2.1. South Africa Key Country Dynamics
      • 8.11.2.2. Regulatory Landscape
      • 8.11.2.3. Competitive Insights
      • 8.11.2.4. South Africa Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.11.3. Saudi Arabia
      • 8.11.3.1. Saudi Arabia Key Country Dynamics
      • 8.11.3.2. Regulatory Landscape
      • 8.11.3.3. Competitive Insights
      • 8.11.3.4. Saudi Arabia Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.11.4. UAE
      • 8.11.4.1. UAE Key Country Dynamics
      • 8.11.4.2. Regulatory Landscape
      • 8.11.4.3. Competitive Insights
      • 8.11.4.4. UAE Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.11.5. Kuwait
      • 8.11.5.1. Kuwait Key Country Dynamics
      • 8.11.5.2. Regulatory Landscape
      • 8.11.5.3. Competitive Insights
      • 8.11.5.4. Kuwait Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Company Market Share Analysis
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles
    • 9.4.1. Lonza
      • 9.4.1.1. Participant's Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Recent Developments
    • 9.4.2. BioIT
      • 9.4.2.1. Participant's Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Recent Developments
    • 9.4.3. Autolomous Ltd
      • 9.4.3.1. Participant's Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Recent Developments
    • 9.4.4. Hypertrust Patient Data Care (Part of Accenture)
      • 9.4.4.1. Participant's Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Recent Developments
    • 9.4.5. IBM
      • 9.4.5.1. Participant's Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Recent Developments
    • 9.4.6. L7 Informatics, Inc.
      • 9.4.6.1. Participant's Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Recent Developments
    • 9.4.7. TrakCel
      • 9.4.7.1. Participant's Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Recent Developments
    • 9.4.8. IDBS
      • 9.4.8.1. Participant's Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Recent Developments
    • 9.4.9. Novartis
      • 9.4.9.1. Participant's Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Recent Developments
    • 9.4.10. SAP SE
      • 9.4.10.1. Participant's Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Recent Developments
    • 9.4.11. DEEP GENOMICS
      • 9.4.11.1. Participant's Overview
      • 9.4.11.2. Financial Performance
      • 9.4.11.3. Product Benchmarking
      • 9.4.11.4. Recent Developments
    • 9.4.12. ElevateBio
      • 9.4.12.1. Participant's Overview
      • 9.4.12.2. Financial Performance
      • 9.4.12.3. Product Benchmarking
      • 9.4.12.4. Recent Developments
    • 9.4.13. Sarepta Therapeutics, Inc.
      • 9.4.13.1. Participant's Overview
      • 9.4.13.2. Financial Performance
      • 9.4.13.3. Product Benchmarking
      • 9.4.13.4. Recent Developments
    • 9.4.14. CRISPR Therapeutics
      • 9.4.14.1. Participant's Overview
      • 9.4.14.2. Financial Performance
      • 9.4.14.3. Product Benchmarking
      • 9.4.14.4. Recent Developments
    • 9.4.15. Precision BioSciences
      • 9.4.15.1. Participant's Overview
      • 9.4.15.2. Financial Performance
      • 9.4.15.3. Product Benchmarking
      • 9.4.15.4. Recent Developments
    • 9.4.16. AstraZeneca
      • 9.4.16.1. Participant's Overview
      • 9.4.16.2. Financial Performance
      • 9.4.16.3. Product Benchmarking
      • 9.4.16.4. Recent Developments
    • 9.4.17. Andelyn Biosciences
      • 9.4.17.1. Participant's Overview
      • 9.4.17.2. Financial Performance
      • 9.4.17.3. Product Benchmarking
      • 9.4.17.4. Recent Developments
    • 9.4.18. Renova Therapeutics
      • 9.4.18.1. Participant's Overview
      • 9.4.18.2. Financial Performance
      • 9.4.18.3. Product Benchmarking
      • 9.4.18.4. Recent Developments